Prot #CUDC-907-201: Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients With MYC Alterations

Project: Research project

StatusActive
Effective start/end date3/3/173/3/20

Funding

  • PRA Health Sciences (Prot #CUDC-907-201)
  • Curis, Inc. (Prot #CUDC-907-201)